Colbran Rachel, Gillespie Christopher, Warwick Andrea
Queen Elizabeth II Jubilee Hospital, Coopers Plains, Qld, Australia.
Faculty of Medicine, University of Queensland, St Lucia, Qld, Australia.
Colorectal Dis. 2022 Apr;24(4):491-496. doi: 10.1111/codi.16037. Epub 2022 Mar 2.
THD SphinKeeper® is an emerging surgical technique for faecal incontinence (FI). The safety, indications and efficacy of the procedure are still being investigated. The aim of this study is to present the first experience of SphinKeeper® in Australia.
This was a prospective single-centre observational study of patients undergoing SphinKeeper® implantation between February 2018 and September 2019. Baseline demographics, intraoperative and postoperative complications, Cleveland Clinic Faecal Incontinence Score, St Mark's Incontinence Score, Faecal Incontinence Quality of Life score (FIQOL), anorectal manometry and endo-anal ultrasound were assessed preoperatively and 3 and 12 months after implantation.
Thirteen patients (2 male, 11 female) underwent implantation during the study period. Anal sphincter defects were present in 13 (76.9%) patients [external anal sphincter (EAS) defect, 2 (15.4%); internal anal sphincter (IAS) defect 4 (30.8%); EAS + IAS defect, 4 (30.8%)]. Median follow-up was 32 months (range 18-37 months). There were four complications: one intraoperative (rectal perforation) and three postoperative (one implant extrusion, two implants that required removal due to malposition). At 12 months, an average of 9/10 implants remained ideally placed in each patient. THD SphinKeeper® insertion was associated with an improvement in coping/behaviour as measured using FIQOL (p = 0.047). However, the procedure did not improve FI scores or anorectal manometry parameters.
In this study, SphinKeeper® marginally improved symptoms of FI but there was no significant impact on anorectal manometric measurements. Larger-scale studies are needed to determine the patient cohort most likely to benefit from this procedure.
SphinKeeper®是一种用于治疗大便失禁(FI)的新兴外科技术。该手术的安全性、适应症和疗效仍在研究中。本研究的目的是介绍澳大利亚首例SphinKeeper®手术的经验。
这是一项对2018年2月至2019年9月期间接受SphinKeeper®植入手术患者的前瞻性单中心观察性研究。术前以及植入后3个月和12个月评估患者的基线人口统计学数据、术中及术后并发症、克利夫兰诊所大便失禁评分、圣马克失禁评分、大便失禁生活质量评分(FIQOL)、肛肠测压和肛门内超声检查结果。
在研究期间,13例患者(2例男性,11例女性)接受了植入手术。13例(76.9%)患者存在肛门括约肌缺陷[肛门外括约肌(EAS)缺陷2例(15.4%);肛门内括约肌(IAS)缺陷4例(30.8%);EAS + IAS缺陷4例(30.8%)]。中位随访时间为32个月(范围18 - 37个月)。出现了4例并发症:1例术中并发症(直肠穿孔)和3例术后并发症(1例植入物挤出,2例因位置不当需要取出的植入物)。在12个月时,平均每位患者有9/10的植入物位置理想。使用FIQOL测量,SphinKeeper®植入与应对/行为改善相关(p = 0.047)。然而,该手术并未改善大便失禁评分或肛肠测压参数。
在本研究中,SphinKeeper®略微改善了大便失禁症状,但对肛肠测压测量结果无显著影响。需要进行更大规模的研究来确定最可能从该手术中获益的患者群体。